<SEC-DOCUMENT>0001279569-17-001415.txt : 20170712
<SEC-HEADER>0001279569-17-001415.hdr.sgml : 20170712
<ACCEPTANCE-DATETIME>20170712164325
ACCESSION NUMBER:		0001279569-17-001415
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170712
FILED AS OF DATE:		20170712
DATE AS OF CHANGE:		20170712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		17962072

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of
1934 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of July
2017</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410
</B></P>

<P STYLE="font: 24pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s
name into English) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway,
Vancouver, British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Form 40-F </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBITS INCLUDED AS PART OF THIS
REPORT </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 87%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 8pt/107% Calibri, Helvetica, Sans-Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit(s)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>NEWS RELEASE DATED JULY 12, 2017: ESSA PHARMA ANNOUNCES OVERNIGHT MARKETED EQUITY OFFERING</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT><FONT STYLE="font-size: 10pt">
        P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT><FONT STYLE="font-size: 10pt"> I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    July 12, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT><FONT STYLE="font-size: 10pt"> W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JULY 12, 2017
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>&nbsp;</B><IMG SRC="essalogo.jpg" ALT="https:||mma.prnewswire.com|media|489324|ESSA_Pharma_Inc_ESSA_to_Present_at_Bloom_Burton___Co_Healthcare.jpg" STYLE="height: 111px; width: 338px"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"><B>ESSA Pharma Announces Overnight Marketed Equity Offering</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">HOUSTON and VANCOUVER, July 12, 2017 /CNW/ -&nbsp;ESSA Pharma
Inc. (TSX: EPI; NASDAQ: EPIX) (&quot;ESSA&quot; or the &quot;Company&quot;), a clinical-stage pharmaceutical company focused on
the development of novel small molecule drugs for the treatment of prostate cancer, announced today that it has undertaken an overnight
marketed public offering (the &quot;Offering&quot;) of securities (the &quot;Securities&quot;) of the Company. The Offering will
be conducted in each of the provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to ESSA's base
shelf prospectus dated December 22, 2015 and elsewhere on a private placement basis. The Securities may also be offered for sale
in the United States through United States registered broker-dealers. The number and type of securities to be distributed under
the Offering and the price of each security will be determined in the context of the market.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The Company expects to close the Offering during the week
of July 17, 2017, subject to satisfaction of customary closing conditions, including, but not limited to, the receipt of all necessary
stock exchange approvals, such as the final approval of the Toronto Stock Exchange and the NASDAQ Capital Market. The net proceeds
of the Offering will be used for the Company's pre-clinical and clinical development of the prostate cancer programs, as well as
for working capital and other general corporate purposes.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The securities described herein have not been registered under
the United States Securities Act of 1933, as amended (the &quot;U.S. Securities Act&quot;), or any state securities laws, and accordingly,
may not be offered or sold to, or for the account or benefit of, persons in the United States or &quot;U.S. persons,&quot; as such
term is defined in Regulation S promulgated under the U.S. Securities Act (&quot;U.S. Persons&quot;), except in compliance with
the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions
therefrom.&nbsp; This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the Company's
securities to, or for the account of benefit of, persons in the United States or U.S. Persons.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>Forward-Looking Statement Disclaimer</B><BR>
<I>This release contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the
meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;anticipate&quot;, &quot;believe&quot;, &quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;,
statements that an action or event &quot;may&quot;, &quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot;
be taken or occur, or other similar expressions and includes, but is not limited to, statements about the timing of the closing
of the Offering, the satisfaction and timing of the receipt of required stock exchange approvals and other conditions to closing
of the Offering, the jurisdictions in which the securities will be offered and the intended use of proceeds of the Offering. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking statements and information are subject
to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which
may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby.
Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are
inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and
contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i)
the accuracy of ESSA's financial projections; (ii) the Phase 1 portion of the Phase 1/2 clinical trial proceeding as expected;
(iii) obtaining positive results of clinical trials; (iv) obtaining necessary regulatory approvals; and (v) general business, market
and economic conditions. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated December 14, 2016
under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile at the SEDAR website at www.sedar.com,
ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile. Forward-looking statements
are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation
to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may
be required by applicable Canadian and United States securities laws. Readers are cautioned against attributing undue certainty
to forward-looking statements. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">View original content with multimedia: http://www.newswire.ca/en/releases/archive/July2017/12/c5996.html</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">%CIK: 0001633932</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information:</B> David S. Wood, Chief Financial Officer,
Tel: (778) 331-0962</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CNW 16:10e 12-JUL-17</P>



<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>essalogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 essalogo.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0(L4&AO=&]S:&]P(#,N,  X0DE-! 0
M     A < G@ +$534T$@4&AA<FUA($EN8RX@*$-.5R!'<F]U<"]%4U-!(%!H
M87)M82!);F,I' ):  =(3U535$].' )T 'U4:&ES(&EM86=E(&UU<W0@8F4@
M=7-E9"!W:71H:6X@=&AE(&-O;G1E>'0@;V8@=&AE(&YE=W,@<F5L96%S92!I
M="!A8V-O;7!A;FEE9"X@4F5Q=65S="!P97)M:7-S:6]N(&9R;VT@:7-S=65R
M(&9O<B!O=&AE<B!U<V5S+AP"90  ' )0  A(86YD+6]U=!P"7P "5%@< AD
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M&#*"D946-T)2559B<G62E*&QL]'3(T-4@Y/2%R0E)C,X8\$T-453HK*T_\0
M' $!  (# 0$!              4& P0' @$(_\0 .Q$  0," @8'!P0!! ,
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M5K]/1L+;+_E0N#XZ,/B=&8]*YOMM^"K8-TW53_EU=_;:G_'=_%/+J[^VU/\
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M-HX[>_G=6SM<TM#FG<'L(Y[K#YAEF,XI;GUV1WV@MD#&[\554-83X-:3NX^
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M=8^_(ZE9SH/F,6>Z2V3*&N;UU92@536_83L\R4>'GM/L(6WJ(WN:6;<%3>L
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,1$1$1$1$1$1$1?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
